Generative Artificial Intelligence Driven Innovation in Drug Molecule Design: Advances and Future Directions

Abstract

The application of generative artificial intelligence (AI) has fundamentally revolutionized the early stages of modern drug discovery by enabling the rapid de novo design of novel drug-like molecules with highly specific and desired pharmacological properties. This comprehensive review systematically examines recent and significant advances in various generative models, including variational autoencoders, generative adversarial networks, autoregressive models, and state-of-the-art diffusion models. Particular emphasis is placed on their seamless integration with advanced molecular representation learning techniques and multi-objective optimization frameworks. Furthermore, key breakthroughs in generating synthetically accessible, target-specific, and pharmacokinetically favorable compounds are critically highlighted and evaluated. We also discuss emerging and transformative trends within the field, such as the deployment of large-scale pre-trained molecular language models, the utilization of reinforcement learning derived from direct chemical feedback, and the implementation of closed-loop wet-lab validation systems. Despite the significant and undeniable progress achieved thus far, substantial challenges remain prevalent in critical areas such as training data quality, practical synthetic feasibility, overall molecular diversity, and algorithmic interpretability. Finally, we outline strategic future directions toward the development of fully autonomous generative design platforms and their real-time integration with high-throughput experimentation workflows. Ultimately, these continuous advancements aim to significantly accelerate the critical transition from AI-generated molecular structures to safe, effective, and clinically viable drug candidates for complex diseases.